Factors | No of patients with teicoplanin initial Cmin ≥20 μg/mL (%) | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|---|
Patients with factor | Patients without factor | Crude odds ratio (95%CI) | P-value | Adjusted odds ratio (95%CI) | P-value | |
Enhanced high loading dose regimen | 117/149 (78.5%) | 150/363 (41.3%) | 5.19 (3.33–8.089) | < 0.001 | 7.75 (4.62–12.99) | < 0.001 |
Sex (male) | 161/318 (50.6%) | 106/194 (54.6%) | 0.85 (0.60–1.22) | 0.378 | ||
Age (> 65 years) | 162/318 (50.9%) | 105/194 (54.1%) | 0.88 (0.62–1.26) | 0.485 | ||
Body mass index< 18.5 | 59/124 (47.6%) | 208/388 (53.6%) | 0.79 (0.52–1.18) | 0.242 | ||
Body mass index ≥25 | 47/74 (63.5%) | 220/438 (50.2%) | 1.73 (1.04–2.87) | 0.034 | 2.33 (1.24–4.38) | 0.008 |
eGFR≥60 mL/min/1.73 m2 | 164/293 (56.0%) | 103/219 (47.0%) | 1.43 (1.01–2.04) | 0.045 | 1.15 (0.68–1.95) | 0.603 |
Heart disease | 111/208 (53.4%) | 156/304 (51.3%) | 1.09 (0.76–1.55) | 0.648 | ||
Chronic renal failure | 47/116 (40.5%) | 220/396 (55.6%) | 0.55 (0.36–0.83) | 0.004 | 0.62 (0.38–1.03) | 0.062 |
Diabetes mellitus | 58/112 (51.8%) | 209/400 (52.3%) | 0.98 (0.65–1.49) | 0.931 | ||
Collagen disease | 25/53 (47.2%) | 242/459 (52.7%) | 0.80 (0.45–1.42) | 0.443 | ||
Chronic respiratory disease | 14/27 (51.9%) | 253/485 (52.2%) | 0.99 (0.46–2.15) | 0.975 | ||
Inflammatory bowel disease | 44/89 (49.4%) | 223/423 (52.7%) | 0.88 (0.56–1.39) | 0.573 | ||
Intensive care unit stay (> 3 days) | 34/98 (34.7%) | 233/414 (56.3%) | 0.41 (0.26–0.65) | < 0.001 | 0.32 (0.19–0.56) | < 0.001 |
Liver cirrhosis/chronic hepatic dysfunction | 34/72 (47.2%) | 233/440 (53.0%) | 0.80 (0.48–1.31) | 0.367 | ||
Malignant tumor | 99/204 (48.5%) | 168/308 (54.5%) | 0.79 (0.55–1.12) | 0.182 | ||
Total parenteral nutrition | 45/102 (44.1%) | 222/410 (54.1%) | 0.70 (0.43–1.03) | 0.070 | 0.54 (0.32–0.92) | 0.022 |
Serum albumin < 2.5 g/dL (median) | 79/217 (36.4%) | 188/295 (63.7%) | 0.33 (0.23–0.47) | < 0.001 | 0.24 (0.15–0.37) | < 0.001 |
Ventilator use | 37/90 (41.1%) | 230/422 (54.5%) | 0.58 (0.37–0.93) | 0.021 | 1.51 (0.68–3.36) | 0.316 |
Surgery within 28 days | 68/158 (43.0%) | 199/354 (56.2%) | 0.59 (0.40–0.86) | 0.006 | 0.47 (0.30–0.74) | 0.001 |
Transplantation | 6/8 (75.0%) | 261/504 (51.8%) | 2.79 (0.56–13.97) | 0.289 | ||
Steroid use | 42/85 (49.4%) | 225/427 (52.7%) | 0.88 (0.55–1.40) | 0.580 | ||
Immunosuppressive therapy | 18/28 (64.3%) | 249/484 (51.4%) | 1.70 (0.77–3.76) | 0.186 | ||
Anticancer therapy | 26/47 (55.3%) | 241/465 (51.8%) | 1.15 (0.63–2.10) | 0.648 | ||
MRSA infections | 72/139 (51.8%) | 195/373 (52.3%) | 0.98 (0.66–1.45) | 0.923 | ||
Complicated MRSA infections | 54/99 (54.5%) | 213/413 (51.6%) | 1.13 (0.73–1.75) | 0.595 | ||
APACHE II score ≥ 15 | 54/130 (41.5%) | 213/382 (55.8%) | 0.56 (0.38–0.84) | 0.005 | 0.78 (0.44–1.35) | 0.371 |